The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Afluria Quadrivalent Market Change Between 2026 And 2030?
Historical growth was driven by the limitations of trivalent influenza vaccines, recurring multi-strain flu outbreaks, increasing hospitalization rates from influenza, established immunization schedules, and public sector vaccination programs.
The expansion anticipated during the forecast period stems from the need for more extensive strain coverage, increased immunization among healthcare workers, the development of pediatric vaccination initiatives, enhanced government acquisition, and innovations in how vaccines are administered. Noteworthy trends projected for this timeframe comprise a growing embrace of quadrivalent influenza vaccines, improved safeguarding against various flu strains, intensified vaccination of susceptible populations, an uptick in governmental immunization efforts, and breakthroughs in vaccine formulation techniques.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19862&type=smp
Which Significant Factors Are Encouraging Growth In The Afluria Quadrivalent Market?
The rising occurrence of influenza is projected to boost the expansion of the afluria quadrivalent market moving forward. Influenza, a contagious respiratory illness caused by viruses, can lead to symptoms ranging from mild to severe, including fever, cough, and body aches. This increased prevalence is influenced by factors such as the virus’s annual mutation, prevailing seasonal environmental conditions, and inadequate vaccination coverage within certain populations. Afluria Quadrivalent plays a vital role in combating this growing prevalence by offering defense against four circulating flu strains, thereby reducing infection risk and lessening the impact of seasonal outbreaks. For example, in November 2024, the UK Health Security Agency, a UK-based government agency, reported that influenza positivity rates in week 46 increased, with a weekly average of 3.9%, up from 3.3% in the preceding week. Individuals aged 5 to 14 exhibited the highest positivity rates, reaching a weekly average of 11.6%, an increase from 8.8% in the prior week (week 45). Consequently, the growing prevalence of influenza is set to stimulate the growth of the afluria quadrivalent market. An increase in birth rates is anticipated to fuel the future growth of the afluria quadrivalent market. The rise in birth rates stems from various elements, including advancements in healthcare, governmental incentives, and shifts in societal perspectives. A greater number of births results in an expanded pediatric population requiring immunizations. As birth rates climb, healthcare systems must administer vaccines to more children to prevent influenza, thereby increasing the demand for vaccines such as Afluria Quadrivalent. For instance, in October 2024, the Australian Bureau of Statistics, an Australia-based government agency, noted that 24,737 Aboriginal and Torres Strait Islander births were registered in 2023, representing an increase of 349 babies from 2022. Thus, increasing birth rates are driving the growth of the afluria quadrivalent market.
What Segment Categories Are Evaluated In The Afluria Quadrivalent Market Study?
The afluria quadrivalent market covered in this report is segmented –
1) By Clinical Indication: Seasonal Influenza Prophylaxis, High-Risk Population Immunization, Pediatric Influenza Prophylaxis, Healthcare Worker Immunization
2) By Route Of Administration: Injection, Nasal Spray
3) By Age Group: Adults, Geriatric, Pediatrics
4) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Channels
5) By End-User: Hospitals, Public, Private, Clinics, Other End-Users
Who Are The Key Market Participants In The Afluria Quadrivalent Market?
Major companies operating in the afluria quadrivalent market are Seqirus Inc.
Access The Complete Afluria Quadrivalent Market Report:
https://www.thebusinessresearchcompany.com/report/afluria-quadrivalent-global-market-report
What Is The Largest Regional Market In The Afluria Quadrivalent Market?
North America was the largest region in the afluria quadrivalent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model